Clinical Trials Browser

Phase EARLY_PHASE1 × Rituximab × Lymphoid × Clear all

NCT05495464 2026-02-27

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

Phase EARLY_PHASE1 Active not recruiting

Lymphoma, Lymphoma, Mantle-Cell

NCT04161248 2026-02-02

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Phase EARLY_PHASE1 Recruiting

Lymphoma, B-Cell

NCT01760226 2025-10-14

DA-EPOCH-R

Phase EARLY_PHASE1 Completed

Lymphoma, Large B-Cell, Diffuse

NCT03295240 2025-05-13

The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma

Phase EARLY_PHASE1 Completed

Lymphoma, Lymphoma, Mantle-Cell

NCT00736450 2023-10-24

Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Phase EARLY_PHASE1 Terminated

37 enrolled 8 charts

Lymphoma, Large B-Cell, Diffuse

NCT02484053 2018-07-11

Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders

Phase EARLY_PHASE1 Completed

Graft vs Host Disease, Hematologic Diseases, Lymphoma

NCT01022021 2017-01-10

Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine

Phase EARLY_PHASE1 Completed

Lymphoma, Lymphoma, Non-Hodgkin

NCT00017381 2013-01-09

Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma

Phase EARLY_PHASE1 Completed

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00734773 2012-05-18

Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL

Phase EARLY_PHASE1 Withdrawn

Lymphoma, Central Nervous System Neoplasms, Neurotoxicity Syndromes

NCT00515138 2012-04-12

A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant

Phase EARLY_PHASE1 Terminated

Lymphoma, B-Cell